Welcome to LookChem.com Sign In|Join Free

CAS

  • or
(R)-3-Methylmorpholine is a chiral organic compound with the molecular formula C5H11NO. It is a colorless liquid with a characteristic amine-like odor and is known for its unique stereochemistry, where the R-configuration denotes the specific arrangement of atoms in its structure. (R)-3-Methylmorpholine is a versatile building block in the synthesis of various pharmaceuticals and agrochemicals due to its ability to form stable intermediates and facilitate complex reactions.

74572-04-6 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 74572-04-6 Structure
  • Basic information

    1. Product Name: (R)-3-Methylmorpholine
    2. Synonyms: (R)-3-Methylmorpholine;(R)-3-MethylmorpholineortheHClsalt;Morpholine, 3-Methyl-, (3R)-;elagolix intermediate 8;Morpholine, 3-methyl-, (R)-;(R)-3-Methylmorpholine(WX900060)
    3. CAS NO:74572-04-6
    4. Molecular Formula: C5H11NO
    5. Molecular Weight: 101.15
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 74572-04-6.mol
  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: 137.1 °C at 760 mmHg
    3. Flash Point: 41.3 °C
    4. Appearance: /
    5. Density: 0.891 g/cm3
    6. Vapor Pressure: 7.14mmHg at 25°C
    7. Refractive Index: 1.409
    8. Storage Temp.: 2-8°C(protect from light)
    9. Solubility: N/A
    10. PKA: 9.03±0.40(Predicted)
    11. CAS DataBase Reference: (R)-3-Methylmorpholine(CAS DataBase Reference)
    12. NIST Chemistry Reference: (R)-3-Methylmorpholine(74572-04-6)
    13. EPA Substance Registry System: (R)-3-Methylmorpholine(74572-04-6)
  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 74572-04-6(Hazardous Substances Data)

74572-04-6 Usage

Uses

Used in Pharmaceutical Industry:
(R)-3-Methylmorpholine is used as a chiral auxiliary and intermediate for the synthesis of complex organic molecules, particularly in the development of enantiomerically pure drugs. Its unique stereochemistry allows for selective reactions, leading to the production of desired enantiomers with high purity and yield.
Used in the Synthesis of (2S)-8-[(3R)-3-Methylmorpholin-4-yl]-1-(3-methyl-2-oxobutyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one:
(R)-3-Methylmorpholine is used as a key component in the discovery and synthesis of (2S)-8-[(3R)-3-Methylmorpholin-4-yl]-1-(3-methyl-2-oxobutyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one, a novel inhibitor of Vps34. (R)-3-Methylmorpholine has potential applications in the treatment of solid tumors, as it targets the Vps34 enzyme, which plays a crucial role in the regulation of cellular processes such as autophagy and vesicle trafficking. By inhibiting Vps34, this compound can disrupt these processes and lead to the suppression of tumor growth and progression.

Check Digit Verification of cas no

The CAS Registry Mumber 74572-04-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,4,5,7 and 2 respectively; the second part has 2 digits, 0 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 74572-04:
(7*7)+(6*4)+(5*5)+(4*7)+(3*2)+(2*0)+(1*4)=136
136 % 10 = 6
So 74572-04-6 is a valid CAS Registry Number.
InChI:InChI=1/C5H11NO/c1-5-4-7-3-2-6-5/h5-6H,2-4H2,1H3/t5-/m1/s1

74572-04-6SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 15, 2017

Revision Date: Aug 15, 2017

1.Identification

1.1 GHS Product identifier

Product name (R)-3-Methylmorpholine

1.2 Other means of identification

Product number -
Other names (3R)-3-methylmorpholine

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:74572-04-6 SDS

74572-04-6Synthetic route

(R)-4-(4-methoxybenzyl)-3-methylmorpholine
954133-47-2

(R)-4-(4-methoxybenzyl)-3-methylmorpholine

(3R)-3-methylmorpholine
74572-04-6

(3R)-3-methylmorpholine

Conditions
ConditionsYield
With palladium on activated charcoal; hydrogen In methanol at 50℃; under 9500.64 Torr; for 18h;83%
(5R)-5-methylmorpholin-3-one
119844-67-6

(5R)-5-methylmorpholin-3-one

(3R)-3-methylmorpholine
74572-04-6

(3R)-3-methylmorpholine

Conditions
ConditionsYield
With lithium aluminium tetrahydride In tetrahydrofuran at 0 - 20℃; for 16h;75%
Stage #1: (5R)-5-methylmorpholin-3-one With lithium aluminium tetrahydride In tetrahydrofuran at 20℃; for 15.5h; Heating / reflux;
Stage #2: With hydrogenchloride; ethanol In tetrahydrofuran
(R)-2-(2-hydroxyethylamino)propan-1-ol

(R)-2-(2-hydroxyethylamino)propan-1-ol

(3R)-3-methylmorpholine
74572-04-6

(3R)-3-methylmorpholine

Conditions
ConditionsYield
Stage #1: (R)-2-(2-hydroxyethylamino)propan-1-ol With sulfuric acid at 140℃; for 14h;
Stage #2: With sodium hydroxide In water at 0℃;
65%
2-(prop-2-yn-1-yloxy)ethan-1-amine
122116-12-5

2-(prop-2-yn-1-yloxy)ethan-1-amine

(3R)-3-methylmorpholine
74572-04-6

(3R)-3-methylmorpholine

Conditions
ConditionsYield
Stage #1: 2-(prop-2-yn-1-yloxy)ethan-1-amine With C42H58N4O2Ti In toluene at 110℃; for 14h; Inert atmosphere; Schlenk technique;
Stage #2: With formic acid; [{(1S,2S-N-p-toluenesulfonyl-1,2-diphenylethanediamine)}(η6-p-cymene)RuCl]; triethylamine In N,N-dimethyl-formamide; toluene at 20℃; for 14h; Inert atmosphere; Schlenk technique; enantioselective reaction;
65%
Multi-step reaction with 2 steps
1: bis(N-2,6-diisoprpylphenylbenzamidato)bis(dimethylamido)titanium (IV) / toluene / 14 h / 110 °C / Inert atmosphere; Glovebox; Schlenk technique; Sealed tube
2: formic acid; [(1S,2S)-N-(p-toluensulfonyl)-1,2-diphenylethanediamine](p-cymene)ruthenium (I); triethylamine / N,N-dimethyl-formamide / 23 °C / Inert atmosphere; Schlenk technique
View Scheme
Multi-step reaction with 2 steps
1: bis(N-2,6-diisoprpylphenylbenzamidato)bis(dimethylamido)titanium (IV) / toluene / 14 h / 110 °C / Inert atmosphere; Glovebox; Schlenk technique; Sealed tube
2: formic acid; silver trifluoromethanesulfonate; [(1S,2S)-N-(p-toluensulfonyl)-1,2-diphenylethanediamine](p-cymene)ruthenium (I); triethylamine / N,N-dimethyl-formamide / 16 h / 23 °C / Inert atmosphere; Schlenk technique
View Scheme
(3R)-3-methyl-4-(phenylmethyl)morpholine
74571-98-5

(3R)-3-methyl-4-(phenylmethyl)morpholine

(3R)-3-methylmorpholine
74572-04-6

(3R)-3-methylmorpholine

Conditions
ConditionsYield
With hydrogen; palladium on activated charcoal at 80℃; under 45600 - 60800 Torr; for 2h;
With hydrogen; palladium 10% on activated carbon In ethanol under 2585.81 Torr;
With hydrogen; hydrogenchloride; palladium 10% on activated carbon In 1,4-dioxane; ethyl acetate under 2068.65 Torr; for 18h;
(R)-2-[Benzyl-(2-hydroxy-ethyl)-amino]-propan-1-ol
74571-95-2

(R)-2-[Benzyl-(2-hydroxy-ethyl)-amino]-propan-1-ol

(3R)-3-methylmorpholine
74572-04-6

(3R)-3-methylmorpholine

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 70percent H2SO4 / 15 h / 140 °C
2: H2 / 10percent Pd/C / 2 h / 80 °C / 45600 - 60800 Torr
View Scheme
(R)-2-bromo-N-(1-hydroxypropan-2-yl)-N-(4-methoxybenzyl)acetamide
1445590-35-1

(R)-2-bromo-N-(1-hydroxypropan-2-yl)-N-(4-methoxybenzyl)acetamide

(3R)-3-methylmorpholine
74572-04-6

(3R)-3-methylmorpholine

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: sodium hydride / tetrahydrofuran / 25 °C / Inert atmosphere
2: lithium aluminium tetrahydride / tetrahydrofuran / Inert atmosphere; Reflux
3: palladium on activated charcoal; hydrogen / methanol / 18 h / 50 °C / 9500.64 Torr
View Scheme
(R)-4-(4-methoxybenzyl)-5-methylmorpholin-3-one
570398-22-0

(R)-4-(4-methoxybenzyl)-5-methylmorpholin-3-one

(3R)-3-methylmorpholine
74572-04-6

(3R)-3-methylmorpholine

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: lithium aluminium tetrahydride / tetrahydrofuran / Inert atmosphere; Reflux
2: palladium on activated charcoal; hydrogen / methanol / 18 h / 50 °C / 9500.64 Torr
View Scheme
3-methylmorpholine
42185-06-8

3-methylmorpholine

C14H15NO4

C14H15NO4

A

C8H15NO2

C8H15NO2

B

(3R)-3-methylmorpholine
74572-04-6

(3R)-3-methylmorpholine

Conditions
ConditionsYield
In dichloromethane at 23℃; Inert atmosphere;
2-chloro-N-(2-hydroxy-1-methyl-ethyl)-acetamide
1057322-63-0

2-chloro-N-(2-hydroxy-1-methyl-ethyl)-acetamide

(3R)-3-methylmorpholine
74572-04-6

(3R)-3-methylmorpholine

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: potassium tert-butylate / dichloromethane; isopropyl alcohol / 1 h / 0 - 20 °C
2: lithium aluminium tetrahydride / tetrahydrofuran / 16 h / 0 - 20 °C
View Scheme
C5H9NO

C5H9NO

A

(S)-3-methylmorpholine
350595-57-2

(S)-3-methylmorpholine

B

(3R)-3-methylmorpholine
74572-04-6

(3R)-3-methylmorpholine

Conditions
ConditionsYield
With [(1S,2S)-N-(p-toluensulfonyl)-1,2-diphenylethanediamine](p-cymene)ruthenium (I); formic acid; silver trifluoromethanesulfonate; triethylamine In N,N-dimethyl-formamide at 23℃; for 16h; Inert atmosphere; Schlenk technique; enantioselective reaction;A n/a
B n/a
C5H9NO

C5H9NO

(3R)-3-methylmorpholine
74572-04-6

(3R)-3-methylmorpholine

Conditions
ConditionsYield
With [(1S,2S)-N-(p-toluensulfonyl)-1,2-diphenylethanediamine](p-cymene)ruthenium (I); formic acid; triethylamine In N,N-dimethyl-formamide at 23℃; Reagent/catalyst; Inert atmosphere; Schlenk technique; enantioselective reaction;n/a
N-(tert-butyloxycarbonyl)-2-(propargyloxy)aminoethane
634926-63-9

N-(tert-butyloxycarbonyl)-2-(propargyloxy)aminoethane

(3R)-3-methylmorpholine
74572-04-6

(3R)-3-methylmorpholine

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: methanol / 0 - 23 °C
2: bis(N-2,6-diisoprpylphenylbenzamidato)bis(dimethylamido)titanium (IV) / toluene / 14 h / 110 °C / Inert atmosphere; Glovebox; Schlenk technique; Sealed tube
3: formic acid; [(1S,2S)-N-(p-toluensulfonyl)-1,2-diphenylethanediamine](p-cymene)ruthenium (I); triethylamine / N,N-dimethyl-formamide / 23 °C / Inert atmosphere; Schlenk technique
View Scheme
Multi-step reaction with 3 steps
1: methanol / 0 - 23 °C
2: bis(N-2,6-diisoprpylphenylbenzamidato)bis(dimethylamido)titanium (IV) / toluene / 14 h / 110 °C / Inert atmosphere; Glovebox; Schlenk technique; Sealed tube
3: formic acid; silver trifluoromethanesulfonate; [(1S,2S)-N-(p-toluensulfonyl)-1,2-diphenylethanediamine](p-cymene)ruthenium (I); triethylamine / N,N-dimethyl-formamide / 16 h / 23 °C / Inert atmosphere; Schlenk technique
View Scheme
4,6-Dichloro-2-(methylthio)pyrimidine
6299-25-8

4,6-Dichloro-2-(methylthio)pyrimidine

(3R)-3-methylmorpholine
74572-04-6

(3R)-3-methylmorpholine

(3R)-4-[6-chloro-2-(methylsulfanyl)pyrimidin-4-yl]-3-methylmorpholine

(3R)-4-[6-chloro-2-(methylsulfanyl)pyrimidin-4-yl]-3-methylmorpholine

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine In dichloromethane at 40℃; for 16h;99%
With N-ethyl-N,N-diisopropylamine In dichloromethane at 40℃;68.1%
3,6-di-bromo-isothiazolo[4,3-b]pyridine

3,6-di-bromo-isothiazolo[4,3-b]pyridine

(3R)-3-methylmorpholine
74572-04-6

(3R)-3-methylmorpholine

(R)-4-(6-bromoisothiazolo[4,3-b]pyridin-3-yl)-3-methylmorpholine

(R)-4-(6-bromoisothiazolo[4,3-b]pyridin-3-yl)-3-methylmorpholine

Conditions
ConditionsYield
In ethanol Reflux;97%
2-chloro-N-methyl-N-(6-(2-morphplino-4-oxo-4H-chromen-8-yl)dibenzo[b,d]thiophen-2-yl)acetamide
1257236-41-1

2-chloro-N-methyl-N-(6-(2-morphplino-4-oxo-4H-chromen-8-yl)dibenzo[b,d]thiophen-2-yl)acetamide

(3R)-3-methylmorpholine
74572-04-6

(3R)-3-methylmorpholine

N-methyl-2-[(3R)-3-methylmorpholin-4-yl]-N-[6-(2-morpholino-4-oxo-4H-chromen-8-yl)dibenzo[b,d]thiophen-2-yl]acetamide
1257234-75-5

N-methyl-2-[(3R)-3-methylmorpholin-4-yl]-N-[6-(2-morpholino-4-oxo-4H-chromen-8-yl)dibenzo[b,d]thiophen-2-yl]acetamide

Conditions
ConditionsYield
With triethylamine In dichloromethane; ISOPROPYLAMIDE at 60℃; for 2h;95%
(1R,2R)-2-(5-(4-bromophenyl)-1H-imidazol-2-yl)cyclopentanecarboxylic acid
1445591-92-3

(1R,2R)-2-(5-(4-bromophenyl)-1H-imidazol-2-yl)cyclopentanecarboxylic acid

(3R)-3-methylmorpholine
74572-04-6

(3R)-3-methylmorpholine

((1R,2R)-2-(5-(4-bromophenyl)-1H-imidazol-2-yl)cyclopentyl)((R)-3-methylmorpholino)methanone
1445590-41-9

((1R,2R)-2-(5-(4-bromophenyl)-1H-imidazol-2-yl)cyclopentyl)((R)-3-methylmorpholino)methanone

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In dichloromethane at 0 - 20℃; for 2h;95%
(1R,2R)-2-(5-(4-bromophenyl)-1H-imidazol-2-yl)-4-methoxycyclopentanecarboxylic acid
1445592-12-0

(1R,2R)-2-(5-(4-bromophenyl)-1H-imidazol-2-yl)-4-methoxycyclopentanecarboxylic acid

(3R)-3-methylmorpholine
74572-04-6

(3R)-3-methylmorpholine

((1R,2R)-2-(5-(4-bromophenyl)-1H-imidazol-2-yl)-4-methoxycyclopentyl)((R)-3-methylmorpholino)methanone
1445590-87-3

((1R,2R)-2-(5-(4-bromophenyl)-1H-imidazol-2-yl)-4-methoxycyclopentyl)((R)-3-methylmorpholino)methanone

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In dichloromethane at 20℃; for 2h;95%
(3R)-3-methylmorpholine
74572-04-6

(3R)-3-methylmorpholine

acetyl chloride
75-36-5

acetyl chloride

1-[(3R)-3-methylmorpholin-4-yl]ethan-1-one
1257237-31-2

1-[(3R)-3-methylmorpholin-4-yl]ethan-1-one

Conditions
ConditionsYield
Stage #1: (3R)-3-methylmorpholine With potassium carbonate In dichloromethane at 20℃; for 0.5h;
Stage #2: acetyl chloride In dichloromethane at 20℃; for 18h;
95%
Stage #1: (3R)-3-methylmorpholine With potassium carbonate In dichloromethane at 0℃; for 0.5h;
Stage #2: acetyl chloride In dichloromethane at 25℃; for 16h;
88%
Stage #1: (3R)-3-methylmorpholine With potassium carbonate In dichloromethane at 20℃; for 0.5h;
Stage #2: acetyl chloride In dichloromethane at 20℃; for 18h;
2,4-dichloro-6-piperidin-1-yl-[1,3,5]triazine
19371-31-4

2,4-dichloro-6-piperidin-1-yl-[1,3,5]triazine

(3R)-3-methylmorpholine
74572-04-6

(3R)-3-methylmorpholine

2-chloro-4-[(3R)-3-methylmorpholin-4-yl]-6-(piperidin-1-yl)-1,3,5-triazine

2-chloro-4-[(3R)-3-methylmorpholin-4-yl]-6-(piperidin-1-yl)-1,3,5-triazine

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine In 1,4-dioxane; dichloromethane at 20℃;95%
(8S)-2-chloro-3-fluoro-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one
1260585-63-4

(8S)-2-chloro-3-fluoro-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one

(3R)-3-methylmorpholine
74572-04-6

(3R)-3-methylmorpholine

(2S)-7-fluoro-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-1,2,3,4-tetrahydropyrimido[1,2-a]pyrimidin-6-one
1523412-61-4

(2S)-7-fluoro-8-[(3R)-3-methylmorpholin-4-yl]-2-(trifluoromethyl)-1,2,3,4-tetrahydropyrimido[1,2-a]pyrimidin-6-one

Conditions
ConditionsYield
at 100℃; for 18h;91%
2,6-Dichloro-4-morpholino-1,3,5-triazine
6601-22-5

2,6-Dichloro-4-morpholino-1,3,5-triazine

(3R)-3-methylmorpholine
74572-04-6

(3R)-3-methylmorpholine

2-chloro-4-[(3R)-3-methylmorpholin-4-yl]-6-(morpholin-4-yl)-1,3,5-triazine

2-chloro-4-[(3R)-3-methylmorpholin-4-yl]-6-(morpholin-4-yl)-1,3,5-triazine

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine In ethanol at 0 - 20℃; Suzuki Coupling;91%
With N-ethyl-N,N-diisopropylamine In ethanol at 0 - 20℃;91%
With N-ethyl-N,N-diisopropylamine In ethanol at 0 - 20℃;
With N-ethyl-N,N-diisopropylamine
1,3,5-trichloro-2,4,6-triazine
108-77-0

1,3,5-trichloro-2,4,6-triazine

(3R)-3-methylmorpholine
74572-04-6

(3R)-3-methylmorpholine

(3R,3′R)-4,4′-(6-chloro-1,3,5-triazine-2,4-diyl)bis(3-methylmorpholine)

(3R,3′R)-4,4′-(6-chloro-1,3,5-triazine-2,4-diyl)bis(3-methylmorpholine)

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine In dichloromethane at 0 - 20℃;91%
With N-ethyl-N,N-diisopropylamine In dichloromethane at 0 - 20℃;91%
In dichloromethane at 0 - 20℃;
(3R)-3-methylmorpholine
74572-04-6

(3R)-3-methylmorpholine

2,4-dichloro-6-(4-nitrophenyl)-1,3,5-triazine
90415-38-6

2,4-dichloro-6-(4-nitrophenyl)-1,3,5-triazine

(R)-4-(4-chloro-6-(4-nitrophenyl)-1,3,5-triazin-2-yl)-3-methylmorpholine

(R)-4-(4-chloro-6-(4-nitrophenyl)-1,3,5-triazin-2-yl)-3-methylmorpholine

Conditions
ConditionsYield
With sodium hydrogencarbonate In water; acetone at 0 - 20℃; for 20h;90%
3-(2,6-difluoropyridin-4-yl)-4-methylaniline

3-(2,6-difluoropyridin-4-yl)-4-methylaniline

(3R)-3-methylmorpholine
74572-04-6

(3R)-3-methylmorpholine

(R)-3-(2-fluoro-6-(3-methylmorpholino)pyridin-4-yl)-4-methylaniline

(R)-3-(2-fluoro-6-(3-methylmorpholino)pyridin-4-yl)-4-methylaniline

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine In dimethyl sulfoxide at 100℃; for 18h;90%
(3R)-3-methylmorpholine
74572-04-6

(3R)-3-methylmorpholine

6-bromo-4-chlorothieno[2,3-d]pyrimidine
56844-12-3

6-bromo-4-chlorothieno[2,3-d]pyrimidine

(R)-4-(6-bromothieno[2,3-d]pyrimidin-4-yl)-3-methylmorpholine

(R)-4-(6-bromothieno[2,3-d]pyrimidin-4-yl)-3-methylmorpholine

Conditions
ConditionsYield
With triethylamine In 1,4-dioxane at 100℃;88%
2,6-dichloropyrimidine-4-carbonitrile

2,6-dichloropyrimidine-4-carbonitrile

(3R)-3-methylmorpholine
74572-04-6

(3R)-3-methylmorpholine

2-chloro-6-[(3R)-3-methylmorpholin-4-yl]pyrimidine-4-carbonitrile

2-chloro-6-[(3R)-3-methylmorpholin-4-yl]pyrimidine-4-carbonitrile

Conditions
ConditionsYield
With triethylamine In dichloromethane at 20℃; for 1.5h;87.47%
(3R,5S)-4-(4,6-dichloro-1,3,5-triazin-2-yl)-3,5-dimethylmorpholine

(3R,5S)-4-(4,6-dichloro-1,3,5-triazin-2-yl)-3,5-dimethylmorpholine

(3R)-3-methylmorpholine
74572-04-6

(3R)-3-methylmorpholine

(3R,5S)-4-(4-chloro-6-((R)-3-methylmorpholino)-1,3,5-triazin-2-yl)-3,5-dimethylmorpholine

(3R,5S)-4-(4-chloro-6-((R)-3-methylmorpholino)-1,3,5-triazin-2-yl)-3,5-dimethylmorpholine

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine In dichloromethane at 0 - 20℃;87%
2,6-dichloro-4-pyrimidinecarboxylic acid
16492-28-7

2,6-dichloro-4-pyrimidinecarboxylic acid

(3R)-3-methylmorpholine
74572-04-6

(3R)-3-methylmorpholine

methyl 2-chloro-6-[(3R)-3-methylmorpholin-4-yl]pyrimidine-4-carboxylate
1233339-69-9

methyl 2-chloro-6-[(3R)-3-methylmorpholin-4-yl]pyrimidine-4-carboxylate

Conditions
ConditionsYield
With triethylamine In dichloromethane at 20℃; for 18h;86%
(3R)-3-methylmorpholine
74572-04-6

(3R)-3-methylmorpholine

2,6-dichloropyrimidine-4-carboxylic acid methyl ester
6299-85-0

2,6-dichloropyrimidine-4-carboxylic acid methyl ester

methyl 2-chloro-6-[(3R)-3-methylmorpholin-4-yl]pyrimidine-4-carboxylate
1233339-69-9

methyl 2-chloro-6-[(3R)-3-methylmorpholin-4-yl]pyrimidine-4-carboxylate

Conditions
ConditionsYield
With triethylamine In dichloromethane at 20℃; for 18h;86%
With triethylamine In dichloromethane at 20℃; for 18h;79.19%
With triethylamine In dichloromethane at 20℃; for 16h; Temperature;70%
With triethylamine In dichloromethane at 20℃; for 18h; Inert atmosphere;9%
2,6-dichloro-3-nitropyridin-4-amine
2897-43-0

2,6-dichloro-3-nitropyridin-4-amine

(3R)-3-methylmorpholine
74572-04-6

(3R)-3-methylmorpholine

(R)-6-chloro-2-(3-methylmorpholino)-3-nitropyridin-4-amine

(R)-6-chloro-2-(3-methylmorpholino)-3-nitropyridin-4-amine

Conditions
ConditionsYield
With triethylamine In N,N-dimethyl acetamide at 80℃; for 3h;86%
bromobenzene
108-86-1

bromobenzene

(3R)-3-methylmorpholine
74572-04-6

(3R)-3-methylmorpholine

(R)-3-methyl-4-phenylmorpholine

(R)-3-methyl-4-phenylmorpholine

Conditions
ConditionsYield
With bis(tri-tert-butylphasphine)palladium dichloride; potassium tert-butylate In toluene for 3h; Reflux;84%
With copper(l) iodide; potassium carbonate; L-proline In dimethyl sulfoxide at 90℃; for 24h;5%
(3R)-3-methylmorpholine
74572-04-6

(3R)-3-methylmorpholine

p-toluenesulfonyl chloride
98-59-9

p-toluenesulfonyl chloride

(R)-3-methyl-4-tosylmorpholine
1438397-95-5

(R)-3-methyl-4-tosylmorpholine

Conditions
ConditionsYield
With triethylamine In dichloromethane at 0 - 20℃;83%
With triethylamine In dichloromethane at 0 - 23℃;
(3R)-3-methylmorpholine
74572-04-6

(3R)-3-methylmorpholine

piperic acid
136-72-1

piperic acid

(2E,4E)-5-(benzo[d][1,3]dioxol-5-yl)-1-((R)-3-methylmorpholino)penta-2,4-dien-1-one

(2E,4E)-5-(benzo[d][1,3]dioxol-5-yl)-1-((R)-3-methylmorpholino)penta-2,4-dien-1-one

Conditions
ConditionsYield
With O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate; N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 20℃; for 8h;83%
(1S,2S)-2-(5-(4-bromophenyl)-1H-imidazol-2-yl)cyclopentanecarboxylic acid hydrochloride

(1S,2S)-2-(5-(4-bromophenyl)-1H-imidazol-2-yl)cyclopentanecarboxylic acid hydrochloride

(3R)-3-methylmorpholine
74572-04-6

(3R)-3-methylmorpholine

((1S,2S)-2-(5-(4-bromophenyl)-1H-imidazol-2-yl)cyclopentyl)((R)-3-methylmorpholino)methanone
1445590-70-4

((1S,2S)-2-(5-(4-bromophenyl)-1H-imidazol-2-yl)cyclopentyl)((R)-3-methylmorpholino)methanone

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In dichloromethane at 20℃; for 2h;82%
2,4,6-trichloropyrimidine
3764-01-0

2,4,6-trichloropyrimidine

(3R)-3-methylmorpholine
74572-04-6

(3R)-3-methylmorpholine

(3R)-4-(2,6-dichloropyrimidin-4-yl)-3-methylmorpholine

(3R)-4-(2,6-dichloropyrimidin-4-yl)-3-methylmorpholine

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine In ethanol at 65℃; for 12h; Cooling with ice;81.2%
With triethylamine In ethanol at 20℃; for 16h;71%
With triethylamine In ethanol at 20℃; for 16h;71%
2,4-dichloro-6-((methylsulfonyl)methyl)pyrimidine

2,4-dichloro-6-((methylsulfonyl)methyl)pyrimidine

(3R)-3-methylmorpholine
74572-04-6

(3R)-3-methylmorpholine

(R)-4-(2-chloro-6-(methylsulfonylmethyl)pyrimidin-4-yl)-3-methylmorpholine
1233339-73-5

(R)-4-(2-chloro-6-(methylsulfonylmethyl)pyrimidin-4-yl)-3-methylmorpholine

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine In dichloromethane at 20℃; for 18h;81%
5,7-dichloro-[1,3]thiazolo[5,4-d]pyrimidine
13479-88-4

5,7-dichloro-[1,3]thiazolo[5,4-d]pyrimidine

(3R)-3-methylmorpholine
74572-04-6

(3R)-3-methylmorpholine

(R)-4-(5-chlorothiazolo[5,4-d]pyrimidin-7-yl)-3-methylmorpholine

(R)-4-(5-chlorothiazolo[5,4-d]pyrimidin-7-yl)-3-methylmorpholine

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine In isopropyl alcohol at 20℃; for 1.5h; Inert atmosphere;80%
ethyl 2-(4-formylphenyl)thiazole-4-carboxylate

ethyl 2-(4-formylphenyl)thiazole-4-carboxylate

(3R)-3-methylmorpholine
74572-04-6

(3R)-3-methylmorpholine

(R)-2-(4-((3-methylmorpholine)methyl)phenyl)thiazole-4-carboxylic acid ethyl ester

(R)-2-(4-((3-methylmorpholine)methyl)phenyl)thiazole-4-carboxylic acid ethyl ester

Conditions
ConditionsYield
Stage #1: ethyl 2-(4-formylphenyl)thiazole-4-carboxylate; (3R)-3-methylmorpholine In dichloromethane at 20 - 30℃; for 0.5h; Inert atmosphere;
Stage #2: With sodium tris(acetoxy)borohydride In dichloromethane at 30℃; for 16h; Cooling with ice;
77.3%
1,3,5-trichloro-2,4,6-triazine
108-77-0

1,3,5-trichloro-2,4,6-triazine

(3R)-3-methylmorpholine
74572-04-6

(3R)-3-methylmorpholine

2,4-dichloro-6-[(3R)-3-methylmorpholin-4-yl]-1,3,5-triazine

2,4-dichloro-6-[(3R)-3-methylmorpholin-4-yl]-1,3,5-triazine

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine In dichloromethane at -50℃; for 2h;76%
With N-ethyl-N,N-diisopropylamine In dichloromethane at -50℃; for 2h;76%
With N-ethyl-N,N-diisopropylamine In dichloromethane at -50℃; for 10h;
4,6-dichloro-5-nitropyrimidine
4316-93-2

4,6-dichloro-5-nitropyrimidine

(3R)-3-methylmorpholine
74572-04-6

(3R)-3-methylmorpholine

(R)-4-(6-chloro-5-nitropyrimidin-4-yl)-3-methylmorpholine

(R)-4-(6-chloro-5-nitropyrimidin-4-yl)-3-methylmorpholine

Conditions
ConditionsYield
With triethylamine In tetrahydrofuran at 0℃; for 0.5h;75%

74572-04-6Relevant articles and documents

Acylative kinetic resolution of racemic methyl-substituted cyclic alkylamines with 2,5-dioxopyrrolidin-1-yl (: R)-2-phenoxypropanoate

Bartashevich, Ekaterina V.,Chulakov, Evgeny N.,Ezhikova, Marina A.,Gruzdev, Dmitry A.,Kodess, Mikhail I.,Korolyova, Marina A.,Krasnov, Victor P.,Levit, Galina L.,Tumashov, Andrey A.,Vakarov, Sergey A.

supporting information, p. 862 - 869 (2022/02/03)

The diastereoselective acylation of a number of racemic methyl-substituted cyclic alkylamines with active esters of 2-phenoxypropanoic acid was studied in detail. The ester of (R)-2-phenoxypropanoic acid and N-hydroxysuccinimide was found to be the most selective agent. The highest stereoselectivity was observed in the kinetic resolution of racemic 2-methylpiperidine in toluene at -40 °C (selectivity factor s = 73) with the predominant formation of (R,R)-amide (93.7% de). To explain the observed stereoselectivity, DFT modelling of the transition states in the reactions of the title acylating agent with 2-methylpiperidine and 2-methylpyrrolidine was performed. The calculated values were in good agreement with experimental data. It has been demonstrated that the acylation proceeds via a concerted mechanism, in which the addition of an amine occurs simultaneously with the elimination of the hydroxysuccinimide fragment. The high stereoselectivity of the (R,R)-amide formation is largely ensured by the lower steric hindrances in the transition states as compared to the formation of (R,S)-amide.

Catalytic Asymmetric Synthesis of Morpholines. Using Mechanistic Insights to Realize the Enantioselective Synthesis of Piperazines

Lau, Ying Yin,Zhai, Huimin,Schafer, Laurel L.

, p. 8696 - 8709 (2016/10/14)

An efficient and practical catalytic approach for the enantioselective synthesis of 3-substituted morpholines through a tandem sequential one-pot reaction employing both hydroamination and asymmetric transfer hydrogenation reactions is described. Starting from ether-containing aminoalkyne substrates, a commercially available bis(amidate)bis(amido)Ti catalyst is utilized to yield a cyclic imine that is subsequently reduced using the Noyori-Ikariya catalyst, RuCl [(S,S)-Ts-DPEN] (η6-p-cymene), to afford chiral 3-substituted morpholines in good yield and enantiomeric excesses of >95%. A wide range of functional groups is tolerated. Substrate scope investigations suggest that hydrogen-bonding interactions between the oxygen in the backbone of the ether-containing substrate and the [(S,S)-Ts-DPEN] ligand of the Ru catalyst are crucial for obtaining high ee's. This insight led to a mechanistic proposal that predicts the observed absolute stereochemistry. Most importantly, this mechanistic insight allowed for the extension of this strategy to include N as an alternative hydrogen bond acceptor that could be incorporated into the substrate. Thus, the catalytic, enantioselective synthesis of 3-substituted piperazines is also demonstrated.

A concise and efficient synthesis of substituted morpholines

Dugar, Sundeep,Sharma, Amit,Kuila, Bilash,Mahajan, Dinesh,Dwivedi, Sandeep,Tripathi, Vinayak

supporting information, (2015/02/19)

A simple and efficient method has been developed for the synthesis of substituted morpholines by a sequence of coupling, cyclization, and reduction reactions of easily available amino alcohols and α-halo acid chlorides. Various mono-, di-, and trisubstituted morpholines, spiro morpholines, and ring-fused morpholines, as well as morpholine homologues, were synthesized in good to excellent yields by a single methodology under similar reaction conditions. The method was also used in a multigram synthesis of (3S)-3-methylmorpholine.

Concerted amidation of activated esters: Reaction path and origins of selectivity in the kinetic resolution of cyclic amines via N-heterocyclic carbenes and hydroxamic acid cocatalyzed acyl transfer

Allen, Scott E.,Hsieh, Sheng-Ying,Gutierrez, Osvaldo,Bode, Jeffrey W.,Kozlowski, Marisa C.

, p. 11783 - 11791 (2014/11/08)

The N-heterocyclic carbene and hydroxamic acid cocatalyzed kinetic resolution of cyclic amines generates enantioenriched amines and amides with selectivity factors up to 127. In this report, a quantum mechanical study of the reaction mechanism indicates that the selectivity-determining aminolysis step occurs via a novel concerted pathway in which the hydroxamic acid plays a key role in directing proton transfer from the incoming amine. This modality was found to be general in amide bond formation from a number of activated esters including those generated from HOBt and HOAt, reagents that are broadly used in peptide coupling. For the kinetic resolution, the proposed model accurately predicts the faster reacting enantiomer. A breakdown of the steric and electronic control elements shows that a gearing effect in the transition state is responsible for the observed selectivity.

NOVEL HEPATITIS C VIRUS INHIBITORS

-

, (2013/07/05)

The invention provides compounds of formula (I): wherein Rings A and A' are independently 5-membered optionally substituted aromatic heterocycles; Q is C(=O)NR1R1' or formula U is C(R4)2, O, S, S(=O)2, C(R4)2C(R4)2, CH2O, OCH2, CH2S, SCH2, CH2S(=O)2, S(=O)CH2 or C=C(Ru )2; X is CH2, CHR12, CR12R12, O, S, S(=O)2 or NRx; m is 0, 1, 2 or 3; n is 0, 1, 2 or 3; the other variables are as defined in the claims, which are of use in the treatment or prophylaxis of hepatitis C virus infection, and related aspects.

Catalytic asymmetric synthesis of substituted morpholines and piperazines

Zhai, Huimin,Borzenko, Andrey,Lau, Ying Yin,Ahn, Shin Hye,Schafer, Laurel L.

supporting information, p. 12219 - 12223 (2013/02/23)

Under two conditions: Hydroamination catalyzed by group 4 metals is featured in the modular and enantioselective synthesis of 3-substituted morpholines and the diastereoselective synthesis of 2,5-substituted piperazines. Copyright

2-AMINOBENZOXAZOLE CARBOXAMIDES AS 5HT3 MODULATORS

-

Page/Page column 21, (2008/12/04)

Compounds of formulae I, II and III: are disclosed as 5-HT3 inhibitors. The compounds are useful in treating CINV, IBS-D and other diseases and conditions.

PYRAZOLE DERIVATIVE

-

Page/Page column 149, (2010/11/27)

A compound represented by Formula (I): wherein Ar1 represents Formula (II): Ar2 represents a 5- or 6-membered aromatic heterocyclic group which may be substituted; and X represents Formula (III): a salt thereof, or a solvate of the compound or the salt. A potent platelet aggregation suppressant which does not inhibit COX-1 and COX-2 is provided.

Phthalazine, aza- and diaza-phthalazine compounds and methods of use

-

Page/Page column 45, (2008/06/13)

The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein A1, A2, B, R1, R2, R3 and R4 are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of kinase mediated diseases including rheumatoid arthritis, psoriasis and other inflammation disorders, as well as intermediates and processes useful for the preparation of compounds of Formula I.

Quinoxaline compounds

-

Page/Page column 19, (2008/06/13)

Certain amidophenyl-sulfonylamino-quinoxaline compounds are CCK2 modulators useful in the treatment of CCK2 mediated diseases.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 74572-04-6